CUBICIN
-
Opinions on drugs -
Posted on
Oct 18 2006
- Updated on
Jan 15 2009
Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use in hospitals
-
Clinical Benefit
Substantial |
The actual benefit of Cubicin is substantial. |
Clinical Added Value
no clinical added value |
According to the available data, it has not been demonstrated that Cubicin provides an improvement in actual benefit compared with the treatments used in the current management of complicated infections of the skin and soft tissues (IAB V). However, it constitutes an additional treatment for the management of those infections |
Contact Us
Évaluation des médicaments